KaydedilenlerDerginizi ekleyin

Dergiler / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 5

Full Recovery of a Child with Fulminant Myocarditisafter Levosimendan Therapy

Hasan SAMSA
Mustafa ARGUN
Mustafa YILMAZ
Onur YILMAZ
Işın SÖNMEZ
Sayfa
505–507
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Levosimendan therapy may offer an effective treatment for children with acute decompensated heart failuresecondary to fulminant myocarditis resistant to standard therapy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Fulminant myocarditis is a rare, life-threatening condition.
📊
Temel Bulgular & Veri:Case Report: We report the full recovery of a 3.5-year-old male patient with an inotrope-resistant heart failure treated withlevosimendan therapy who was diagnosed as having fulminant myocarditis after presenting with acute decompensated heartfailure and low cardiac output.
💡
Sonuç & Katkı:Conclusion: Levosimendan therapy may offer an effective treatment for children with acute decompensated heart failuresecondary to fulminant myocarditis resistant to standard therapy.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: Fulminant myocarditis is a rare, life-threatening condition. Decompensated heart failure caused by fulminantmyocarditis is managed with inotropic agents, mechanical ventilation, and mechanical circulatory support. Levosimendan isa novel inotropic agent that also has vasodilatory and cardioprotective properties. However, information about levosimendanuse in children is limited in the literature. Case Report: We report the full recovery of a 3.5-year-old male patient with an inotrope-resistant heart failure treated withlevosimendan therapy who was diagnosed as having fulminant myocarditis after presenting with acute decompensated heartfailure and low cardiac output. Conclusion: Levosimendan therapy may offer an effective treatment for children with acute decompensated heart failuresecondary to fulminant myocarditis resistant to standard therapy.

🔖

Bu Makaleye Atıf Yap

SAMSA, H., ARGUN, M., YILMAZ, M., YILMAZ, O., SÖNMEZ, I. (2022). Full Recovery of a Child with Fulminant Myocarditisafter Levosimendan Therapy. Erciyes Medical Journal, Cilt: 43 - Sayı: 5, 505–507. https://ajindex.com/articles/502263

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Howard A, Hasan A, Brownlee J, Mehmood N, Ali M, Mehta S, et al. Pediatric myocarditis protocol: An algorithm for early ıdentification and management with retrospective analysis for validation. Pediatr Cardiol 2020; 41(2): 316–26
  2. Di Filippo S. Improving outcomes of acute myocarditis in children. Expert Rev Cardiovasc Ther 2016; 14(1): 117–25
  3. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical features of acute and fulminant myocarditis in children- 2nd Nationwide survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circ J 2016; 80(11): 2362–8
  4. Şık G, Annayev A, Demirbuğa A, Deliceo E, Aydın S, Erek E, et al. Extracorporeal membrane oxygenation for the support of pediatric patients with acute fulminant myocarditis. Turk J Pediatr 2019; 61(6): 867–72
  5. Veronese G, Ammirati E, Cipriani M, Frigerio M. Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatol J Cardiol 2018;19(4): 279–86
  6. Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol 2016; 222: 303–12
  7. Wang A, Cui C, Fan Y, Zi J, Zhang J, Wang G, et al. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial. Crit Care 2019; 23(1): 428
  8. Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013; 5(4): 227–45
  9. Vilaboa Pedrosa C, Martínez Roca C, Yáñez Gómez P, Martín Herranz MI. Experience with levosimendan in 32 paediatric patients. Pediatr Cardiol 2015; 36(5): 1038–41
  10. Kushwah S, Kumar A, Sahana KS. Levosimendan. A promising future drug for refractory cardiac failure in children?. Indian Heart J 2016; 68(Suppl 1): S57–S60.